Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.75% $4.85
America/New_York / 17 apr 2024 @ 13:41
FUNDAMENTALS | |
---|---|
MarketCap: | 44.74 mill |
EPS: | -7.64 |
P/E: | -0.630 |
Earnings Date: | May 14, 2024 |
SharesOutstanding: | 9.23 mill |
Avg Daily Volume: | 0.0159 mill |
RATING 2024-04-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.630 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.11x |
Company: PE -0.630 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$6.95 (43.25%) $2.10 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 4.44 - 5.26 ( +/- 8.37%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-21 | Kropotova Alexandra | Buy | 140 000 | Employee Stock Option (right to buy) |
2024-02-21 | Sullivan Eddie Joe | Buy | 190 000 | Employee Stock Option (right to buy) |
2024-02-21 | Bausch Christoph Lawrence | Buy | 140 000 | Employee Stock Option (right to buy) |
2024-02-21 | King Michael | Buy | 115 000 | Employee Stock Option (right to buy) |
2024-02-21 | Reich Samuel J | Buy | 434 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
70.16 |
Last 88 transactions |
Buy: 19 783 333 | Sell: 3 137 658 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $4.85 (2.75% ) |
Volume | 0.0031 mill |
Avg. Vol. | 0.0159 mill |
% of Avg. Vol | 19.79 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.